Lisinopril compositions with an ingestible event marker

An ingestible composition comprising:

• 1) about 10% w/w lisinopril;
• about 15% w/w dicalcium phosphate, dihydrate;
• about 53.85% w/w mannitol (50 um);
• about 10% w/w pregelatinized starch;
• OR
• 2) about 7.3% w/w lisinopril;
• about 30% w/w dicalcium phosphate, dihydrate;
• about 24.6% w/w mannitol (50 um);
• about 20% w/w pregelatinized starch;
• OR
• 3) about 10.21% w/w lisinopril;
• about 15.31% w/w dicalcium phosphate, dihydrate;
• about 58.02% w/w mannitol (180 um);
• about 15.31% w/w pregelatinized starch;
• OR
• 4) about 9.69% w/w lisinopril;
• about 14.53% w/w dicalcium phosphate, dihydrate;
• about 55.09% w/w mannitol (180 um);
• about 14.53% w/w pregelatinized starch;
• OR
• 5) about 9.18% w/w lisinopril;
• about 13.76% w/w dicalcium phosphate, dihydrate;
• about 52.16% w/w mannitol (180 um);
• about 13.76% w/w pregelatinized starch;
• OR
• 6) about 18.18% w/w lisinopril;
• about 1318% w/w dicalcium phosphate, dihydrate;
• about 47.59% w/w mannitol (50 um);
• about 10% w/w pregelatinized starch;
• OR
• 7) about 18.18% w/w lisinopril;
• about 14.32% w/w dicalcium phosphate, dihydrate;
• about 51.36% w/w mannitol (50 um);
• about 5% w/w pregelatinized starch;
• OR
• 8) about 7.27% w/w lisinopril;
• about 30% w/w dicalcium phosphate, dihydrate;
• about 24.58% w/w mannitol (50 um);
• about 20% w/w pregelatinized starch;
• OR
• 9) about 10% w/w lisinopril;
• about 28% w/w dicalcium phosphate, dihydrate;
• about 22.85% w/w mannitol (50 um);
• about 20% w/w pregelatinized starch;
• OR
• 10) about 10.26% w/w lisinopril;
• about 15.38% w/w dicalcium phosphate, dihydrate;
• about 58.32% w/w mannitol (180 um);
• about 15.38% w/w pregelatinized starch;
• OR
• 11) about 10.16% w/w lisinopril;
• about 15.23% w/w dicalcium phosphate, dihydrate;
• about 57.73% w/w mannitol (180 um);
• about 15.23% w/w pregelatinized starch;
• OR
• 12) about 10.05% w/w lisinopril;
• about 15.07% w/w dicalcium phosphate, dihydrate;
• about 57.14% w/w mannitol (180 um);
• about 15.07% w/w pregelatinized starch;
• OR
• 13) about 10.1% w/w lisinopril;
• about 15.15% w/w dicalcium phosphate, dihydrate;
• about 57.44% w/w mannitol (180 um);
• about 15.15% w/w pregelatinized starch;
• OR
• 14) about 10% w/w lisinopril;
• about 15% w/w dicalcium phosphate, dihydrate;
• about 56.85% w/w mannitol (180 um);
• about 15% w/w pregelatinized starch;
• OR
• 15) about 9.74% w/w lisinopril;
• about 14.61% w/w dicalcium phosphate, dihydrate;
• about 55.39% w/w mannitol (180 um);
• about 14.61% w/w pregelatinized starch;
• OR
• 16) about 10.62% w/w lisinopril;
• about 15.92% w/w dicalcium phosphate, dihydrate;
• about 57.18% w/w mannitol (180 um);
• about 10.62% w/w pregelatinized starch;
• OR
• 17) about 10.06% w/w lisinopril;
• about 15.08% w/w dicalcium phosphate, dihydrate;
• about 54.16% w/w mannitol (180 um);
• about 10.06% w/w pregelatinized starch;
• and
• an ingestible identifier comprising:
• an integrated circuit comprising silicon, aluminum, silicon dioxide, and silicon nitride;
• a wafer comprising titanium, titanium-tungsten, gold, magnesium, copper (I) chloride, and hydroxypropyl cellulose;
• and
• a skirt film comprising ethyl cellulose, hydroxypropyl cellulose, and triethyl citrate.